Altimmune (NASDAQ:ALT) Lowered to Neutral at Guggenheim

Altimmune (NASDAQ:ALT) was downgraded by equities research analysts at Guggenheim from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat Ratings reports.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group began coverage on Altimmune in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective for the company. B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Thursday, March 28th. Finally, HC Wainwright lowered their price objective on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, April 1st.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $6.55 on Monday. The business has a fifty day moving average of $9.24 and a two-hundred day moving average of $7.61. Altimmune has a 52-week low of $2.09 and a 52-week high of $14.84. The stock has a market cap of $464.36 million, a PE ratio of -3.97 and a beta of 0.05.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. The firm had revenue of $0.04 million for the quarter. Altimmune had a negative net margin of 20,780.75% and a negative return on equity of 44.77%. Analysts predict that Altimmune will post -1.52 earnings per share for the current year.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Barclays PLC lifted its stake in shares of Altimmune by 62.0% in the 3rd quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after purchasing an additional 69,014 shares during the period. Timelo Investment Management Inc. grew its position in shares of Altimmune by 2,597.0% during the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after buying an additional 779,095 shares during the period. GSA Capital Partners LLP boosted its position in shares of Altimmune by 153.1% during the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Altimmune in the 4th quarter valued at $534,000. Finally, Dark Forest Capital Management LP increased its position in shares of Altimmune by 13.4% in the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock valued at $599,000 after buying an additional 27,210 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.